OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biologics licensing company focused on antibody discovery technologies, operating its proprietary OmniAb platform to help pharmaceutical and biopharmaceutical partners generate therapeutic antibody candidates across multiple modalities. The company entered the public markets in November 2022 through a business combination with Avista Public Acquisition Corp. II, a blank-check vehicle sponsored by Avista Capital Partners that completed its IPO in 2021. OmniAb operates within the biotechnology sector and submitted an 8-K filing with the SEC on August 6, 2026, under accession number 0001846253-26-000044. To access full filing history, deal terms, and analytics on OABI and the broader SPAC universe, sign up for complete data at SpacDesk.